Genmab A/S has entered into a licensing deal and equity investment with Johnson & Johnson Inc potentially valued at $1.1 billion for an early-stage antibody that targets CD38, a molecule that is highly expressed on multiple myeloma cells. The deal is the largest partnership in the Danish company’s history.
